Millennium: The Takeda Oncology Company introduces the VELCADE® (bortezomib) for Professionals app. This app was designed to offer healthcare professionals greater access to tools and information for VELCADE. It will allow you to:

-Stay up to date on news and updates for VELCADE
-Quickly access dosing and administration information for VELCADE
-View and order educational resources for your patients
-Review key pivotal trial publications for VELCADE
-Contact Millennium by phone or e-mail
-Obtain general guidance about reimbursement, patient access to treatment, the VELCADE Reimbursement Assistance Program, and view sample reimbursement forms and letters
-Make your opinion known with our interactive polling station

Please note:
This app is available for US health care professionals ONLY.

Indications and Important Safety Information VELCADE® (bortezomib)

INDICATIONS
VELCADE (bortezomib) is indicated for the treatment of patients with multiple myeloma. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.

CONTRAINDICATIONS
VELCADE (bortezomib) is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol, including anaphylactic reactions. VELCADE is contraindicated for intrathecal administration.

WARNINGS, PRECAUTIONS, AND DRUG INTERACTIONS
-Peripheral neuropathy: Manage with dose modification or discontinuation. Patients with preexisting severe neuropathy should be treated with VELCADE only after careful risk-benefit assessment.
-Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration.
-Cardiac toxicity: Worsening of and development of cardiac failure have occurred. Closely monitor patients with existing heart disease or risk factors for heart disease.
-Pulmonary toxicity: Acute respiratory syndromes have occurred. Monitor closely for new or worsening symptoms.
-Posterior reversible encephalopathy syndrome: Consider MRI imaging for onset of visual or neurological symptoms; discontinue VELCADE if suspected.
-Gastrointestinal toxicity: Nausea, diarrhea, constipation, and vomiting may require use of antiemetic and antidiarrheal medications or fluid replacement.
-Thrombocytopenia or Neutropenia: Monitor complete blood counts regularly throughout treatment.
-Tumor lysis syndrome: Closely monitor patients with high tumor burden.
-Hepatic toxicity: Monitor hepatic enzymes during treatment.
-Embryo-fetal risk: Women should avoid becoming pregnant while being treated with VELCADE. Advise pregnant women of potential embryo fetal harm.
Closely monitor patients receiving VELCADE in combination with strong CYP3A4 inhibitors. Avoid concomitant use of strong CYP3A4 inducers.
ADVERSE REACTIONS
Most commonly reported adverse reactions (incidence ≥20%) in clinical studies include nausea, diarrhea, thrombocytopenia, neutropenia, peripheral neuropathy, fatigue, neuralgia, anemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia.
Please see full Prescribing Information for VELCADE at:
http://www.velcade.com/Files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf

V-12-0380b